RE-BVS – Piemonte Repository

Sfoglia per AUTORE
BARONE C
Collezione AO Cuneo

Items : 5

Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Oct;22(10):1458-1467. doi: 10.1016/S1470-2045(21)00352-1. Epub 2021 Sep 17.

2021
AO Cuneo
AOU Città della Salute di Torino

Bruzzi P; Montemurro F; Ballestrero A; Lambertini M; Amaducci L; Campadelli E; Arpino G; Moretti G; Tamberi S; Bighin C; Puglisi F; Barone C; Garrone O; Fabi A; Gori S; De Placido S; Urracci Y; Sanna G; Mura S; Michelotti A; Poggio F; Frassoldati A; Cognetti F; Durando A; Ponzone R; Del Mastro L; Mansutti M; Bisagni G;

Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. in The breast journal / Breast J. 2019 May;25(3):444-449. doi: 10.1111/tbj.13240. Epub 2019 Apr 1.

2019
ASL Torino 5
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
ASL Vercelli

Bonzano A; Milani A; D'Alonzo A; Bellini E; Pizzuti L; Barone C; Del Mastro L; Garrone O; Airoldi M; Vici P; Becco P; Martinello R; Montemurro F;

Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. in Oncotarget / Oncotarget. 2017 Aug 10;8(45):79884-79896. doi: 10.18632/oncotarget.20168. eCollection 2017 Oct 3.

2017
AO Cuneo

Gamucci T; Quadrini S; Palazzo S; Di Cicilia R; Cavanna L; Rubino D; Pinto C; Maiorana L; Iacono C; Imperatori M; Tonini G; Bergo E; Zagonel V; Marchetti L; Pavese I; Chiurazzi B; Carteni G; Magarotto R; Gori S; Plastino F; Barone C; Saracino V; Lorusso V; Farcomeni A; Lucia S; Muscaritoli M; Minardi S; Merlano M; Colucci G; et alii...

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Jun;26(6):1188-1194. doi: 10.1093/annonc/mdv112. Epub 2015 Feb 23.

2015
AO Cuneo
AOU Città della Salute di Torino

Cremolini C; Loupakis F; Antoniotti C; Lonardi S; Masi G; Salvatore L; Cortesi E; Tomasello G; Spadi R; Zaniboni A; Tonini G; Barone C; Vitello S; Longarini R; Bonetti A; D'Amico M; Di Donato S; Granetto C; Boni L; Falcone A;

Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study in Journal of Clinical Oncology

2014
AO Cuneo

Loupakis F; Cremolini C; Lonardi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Valsuani C; Chiara S; Boni C; Marcucci L; Negri F; Barone C; Vitello S; D'Amico M; Granetto C; Fontanini G; Tomcikova D; Boni L; Falcone A;